Evidence map›Paper›PMID 37197964›Full record

ArticleInternal medicine (Tokyo, Japan)2024

An Iron-chelating Agent Improved the Cardiac Function in a Patient with Severe Heart Failure Due to Hereditary Hemochromatosis.

Akito Setoguchi, Hiroaki Kawano, Shinji Okano, Tomohiro Honda, Takeharu Kato, Sumito Dateki, Akira Senoo, Yomi Nakashima, Tetsufumi Motokawa, Yuki Ueno and 6 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Akito SetoguchiDepartment of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Hiroaki KawanoDepartment of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Shinji OkanoDepartment of Pathology, Nagasaki University Hospital, Japan.
Tomohiro HondaDepartment of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Takeharu KatoDepartment of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Sumito DatekiDepartment of Pediatrics, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Akira SenooDivision of Electron Microscopy, Pathology and Cytology Laboratories, Japan.
Yomi NakashimaDepartment of Endocrinology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Tetsufumi MotokawaDepartment of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Yuki UenoDepartment of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Ryohei AkashiDepartment of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Tsuyoshi YonekuraDepartment of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Eijun SueyoshiDepartment of Radiology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Satoshi IkedaDepartment of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Yasushi MiyazakiDepartment of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Koji MaemuraDepartment of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Nagasaki University · JPNagasaki University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 24-year-old man was admitted to our hospital because of severe heart failure. Although he was treated with diuretics and positive inotropic agents, his heart failure progressed. An endomyocardial biopsy revealed iron deposition in his myocytes. Finally, he was diagnosed with hereditary hemochromatosis. After starting administration of an iron-chelating agent in addition to conventional treatment for heart failure, his condition improved. We should consider hemochromatosis in heart failure patients with severe right ventricular dysfunction in addition to left ventricular dysfunction.

Indexed as

Heart FailureHemochromatosisAdultHeartHumansIronIron Chelating AgentsMaleYoung AdultIronIron Chelating Agentscardiomyopathyiron overloadtricuspid regurgitation

Identifiers

PMID37197964
PMCPMC10864071
OpenAlexW4377007570

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.